Literature DB >> 32994055

Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.

John K Chan1, Su-Ying Liang2, Daniel S Kapp3, Joshua E Chan3, Thomas J Herzog4, Robert L Coleman5, Bradley J Monk6, Michael T Richardson7.   

Abstract

Entities:  

Keywords:  Maintenance therapy; Ovarian neoplasms; Poly(ADP-ribose) polymerase inhibitors

Year:  2020        PMID： 32994055     DOI： 10.1016/j.ygyno.2020.09.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  2 in total

1.  Report from the 36th Annual Meeting of the Korean Society of Gynecologic Oncology (KSGO).

Authors:  Ju Hyun Kim; Joseph J Noh; Kyung Jin Eoh; Young Tae Kim
Journal:  J Gynecol Oncol       Date:  2021-07       Impact factor: 4.401

Review 2.  Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Domenica Lorusso; Holly Guy; Yevgeniy Samyshkin; Carol Hawkes; Kasey Estenson; Robert L Coleman
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.